Back to Results

Seer Inc (SEER)

Seer, Inc. is a healthcare company focused on life sciences tools and services, with common stock listed on NASDAQ under the ticker SEER. The company develops and commercializes products designed to analyze the proteome and support research into human biology and health. Its product portfolio includes the Proteograph Product Suite, which combines engineered nanoparticles, consumables, automation instrumentation, and data analysis software for proteomic research use. Seer also offers Proteograph ONE, a third-generation assay, Proteograph DIRECT for automated sample digestion in bottom-up LC-MS proteomic analysis, and the Proteograph Analysis Suite, a cloud-based analytics platform for quality control, data management, and interpretation of results. The company markets its products for research use only to academic institutions, life sciences and research laboratories, and biopharmaceutical and biotechnology companies. Seer was incorporated in 2017, formerly operated as Seer Biosciences, Inc., and is headquartered in Redwood City, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-SEER
$3.08
49.9% Upside
Undervalued
$4
94.6% Upside
Bargain
Fair
—
—
—
0.0%
August 6, 2026
-1.6x
0.5x
7.5x
112.2 M
-30.657 M
17.0%
72.9%
8.0
—
70.8%
Send a message
Valuation • Fair Value

Seer Inc (NASDAQ-SEER) Fair Value by Valuation Model

Compare the primary fair value estimate for Seer Inc (NASDAQ-SEER) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.08

Estimated upside of 49.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.47

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$3.28

Comparable-company valuation reference.

Analyst Price Target

$4

Analysts imply upside of 94.6%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Seer Inc (NASDAQ-SEER) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Seer Inc (NASDAQ-SEER)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

15.166 M

Current operating scale indicator.

Revenue Forecast

16.25 M

Forward revenue estimate.

EBITDA

-68.484 M

Current operating profitability reference.

EBITDA Forecast

-33.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Seer Inc (NASDAQ-SEER) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Seer Inc (NASDAQ-SEER)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-2.89

No elevated caution signal from this screen.

Altman Z-Score

8.0

Relatively strong balance-sheet zone.

FCF / Net Income

70.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Seer Inc (NASDAQ-SEER). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Seer Inc (NASDAQ-SEER)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Seer Inc (NASDAQ-SEER), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Seer Inc (NASDAQ-SEER) Stock Forecast & Technical Outlook

Review Seer Inc (NASDAQ-SEER) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Seer Inc (NASDAQ-SEER) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Seer Inc (NASDAQ-SEER) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Seer Inc (NASDAQ-SEER) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Seer Inc (NASDAQ-SEER) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for Seer Inc (NASDAQ-SEER) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Seer Inc (NASDAQ-SEER)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Seer Inc (NASDAQ-SEER) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

Seer Inc (NASDAQ-SEER) Stock FAQ

Quick answers about Seer Inc (NASDAQ-SEER) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.08
Estimated upside 49.9%
Valuation Rating
Undervalued
Estimated upside of 49.9%
Analyst Target
$4
Implied upside 94.6%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Seer Inc (NASDAQ-SEER) is $3.08. This implies an estimated upside of 49.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 49.9% versus the current market price.

The available analyst price target for Seer Inc (NASDAQ-SEER) is $4. The analyst target implies estimated upside of 94.6%.

The current financial health read for Seer Inc (NASDAQ-SEER) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Seer Inc (NASDAQ-SEER) is August 6, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Seer Inc (NASDAQ-SEER) is -1.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Seer Inc is 112.2 M.

The current enterprise value listed for Seer Inc is -30.657 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Seer Inc is NASDAQ-SEER, and the stock is listed on NASDAQ.

Seer Inc (NASDAQ-SEER) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Seer Inc is 17.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Seer Inc is 72.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NASDAQ View more

Illumina Inc (ILMN) Illumina Inc (ILMN)
Medpace Holdings Inc (MEDP) Medpace Holdings Inc (MEDP)
ICON PLC (ICLR) ICON PLC (ICLR)
Bio-Techne Corp (TECH) Bio-Techne Corp (TECH)
Tempus AI Inc (TEM) Tempus AI Inc (TEM)
Bruker Corporation (BRKR) Bruker Corporation (BRKR)
Repligen Corporation (RGEN) Repligen Corporation (RGEN)
10X Genomics Inc (TXG) 10X Genomics Inc (TXG)
Sotera Health Co (SHC) Sotera Health Co (SHC)
Adaptive Biotechnologies Corp (ADPT) Adaptive Biotechnologies Corp (ADPT)
Maravai Lifesciences Holdings Inc (MRVI) Maravai Lifesciences Holdings Inc (MRVI)
Abcellera Biologics Inc (ABCL) Abcellera Biologics Inc (ABCL)
Fortrea Holdings Inc (FTRE) Fortrea Holdings Inc (FTRE)
BioLife Solutions Inc (BLFS) BioLife Solutions Inc (BLFS)
Personalis Inc (PSNL) Personalis Inc (PSNL)
Azenta Inc (AZTA) Azenta Inc (AZTA)
Cryoport Inc (CYRX) Cryoport Inc (CYRX)
Evotec SE ADR (EVO) Evotec SE ADR (EVO)
Cytek Biosciences Inc (CTKB) Cytek Biosciences Inc (CTKB)
Mesa Laboratories Inc (MLAB) Mesa Laboratories Inc (MLAB)
Pacific Biosciences of California (PACB) Pacific Biosciences of California (PACB)
Standard Biotools Inc (LAB) Standard Biotools Inc (LAB)
OmniAb Inc (OABI) OmniAb Inc (OABI)
Alpha Teknova Inc (TKNO) Alpha Teknova Inc (TKNO)